TABLE 1.
Baseline clinical characteristics
|
Placebo (N = 138) |
Tezepelumab 210 mg Q4W (N = 137) |
Pooled tezepelumab (N = 412) |
|
|---|---|---|---|
| Blood eosinophil count, cells/μl | |||
| Mean (±SD) | 380 (328) | 365 (351) | 367 (361) |
| Median (min, max) | 275 (0, 1,870) | 280 (0, 3,180) | 280 (0, 3,990) |
| FeNO, ppb | |||
| Mean (±SD) | 37.8 (39.7) | 31.5 (29.8) | 33.5 (38.1) |
| Median (min, max) | 22.0 (3.5, 276.3) | 22.0 (4.0, 152.5) | 22.0 (2.0, 349.0) |
| IgE, IU/ml | |||
| Mean (±SD) | 474.5 (1,271.6) | 483.9 (1,402.5) | 388.2 (1,018.4) |
| Median (min, max) | 148.2 (6.0, 11,859.6) | 135.4 (2.0, 11,429.6) | 129.6 (2.0, 11,429.6) |
| IL−5, pg/ml | |||
| n | 132 | 126 | 255 |
| Mean (±SD) | 1.13 (1.77) | 1.88 (7.33) | 1.47 (5.23) |
| Median (min, max) | 0.66 (0.03, 15.00) | 0.68 (0.04, 80.16) | 0.60 (0.03, 80.16) |
| IL−13, pg/ml | |||
| n | 101 | 89 | 294 |
| Mean (±SD) | 0.06 (0.08) | 0.06 (0.09) | 0.07 (0.11) |
| Median (min, max) | 0.04 (0.008, 0.63) | 0.03 (0.008, 0.63) | 0.04 (0.008, 1.33) |
| Periostin, ng/ml | |||
| Mean (±SD) | 23.1 (10.1) | 23.2 (10.4) | 22.9 (11.0) |
| Median (min, max) | 20.9 (8.6, 76.1) | 22.0 (6.2, 63.9) | 21.1 (6.2, 107.6) |
| TARC, pg/ml | |||
| n | 137 | 133 | 266 |
| Mean (±SD) | 415.3 (297.0) | 405.7 (254.9) | 411.8 (264.8) |
| Median (min, max) | 315.8 (65.4, 1,795.8) | 342.5 (94.9, 1,300.9) | 351.3 (36.5, 2,000.0) |
| TSLP, fg/ml | |||
| n | 138 | 136 | 408 |
| Mean (±SD) | 355.0 (178.7) | 422.8 (289.8) | 376.3 (353.8) |
| Median (min, max) | 313.6 (66.3, 969.8) | 355.0 (65.5, 2,260.0) | 303.5 (19.5, 4,735.8) |
Abbreviations: FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E; IL, interleukin; ppb, parts per billion; Q4W, every 4 weeks; SD, standard deviation; TARC, thymus and activation‐regulated chemokine; TSLP, thymic stromal lymphopoietin.